Total 2 articles
Big Pharma faces a $171B revenue cliff. Their solution? Chinese biotech. Our analysis unpacks the high-stakes clash between economic need and geopolitical risk.
The 2025 US defense bill codifies a tech and capital blockade against China. This analysis explores the impact on biotech, VC, and global supply chains.
Advertise with Us
